TREATMENT SET TS349930 injection, solution TREATMENT SET TS349931 injection, solution TREATMENT SET TS349945- treatment set ts

Pays: États-Unis

Langue: anglais

Source: NLM (National Library of Medicine)

Achète-le

Ingrédients actifs:

PLANTAGO LANCEOLATA POLLEN (UNII: DO87T1U2CI) (PLANTAGO LANCEOLATA POLLEN - UNII:DO87T1U2CI), CHENOPODIUM ALBUM POLLEN (UNII: 098LKX5NCN) (CHENOPODIUM ALBUM POLLEN - UNII:098LKX5NCN), URTICA DIOICA POLLEN (UNII: DNB59M1NVU) (URTICA DIOICA POLLEN - UNII:DNB59M1NVU), AMARANTHUS RETROFLEXUS POLLEN (UNII: 73B14PX5FW) (AMARANTHUS RETROFLEXUS POLLEN - UNII:73B14PX5FW), AMBROSIA ARTEMISIIFOLIA POLLEN (UNII: K20Y81ACO3) (AMBROSIA ARTEMISIIFOLIA POLLEN - UNII:K20Y81ACO3), CYNODON DACTYLON POLLEN (UNII: 175F461W

Disponible depuis:

Antigen Laboratories, Inc.

DCI (Dénomination commune internationale):

PLANTAGO LANCEOLATA POLLEN

Composition:

PLANTAGO LANCEOLATA POLLEN 0.002 g in 1 mL

Mode d'administration:

SUBCUTANEOUS

indications thérapeutiques:

When the natural exposure to elevated aeroallergens produces symptoms as described under Clinical Pharmacology, specific diagnosis and therapeutic procedures are indicated. Clearly, important clues to the cause of a person's allergic condition can be gleaned from a thorough history and careful physical examination. Diagnostic tests - in vitro or in vivo - serve only to confirm the physician's suspicions or to improve investigative skills. Specific diagnosis is especially indicated when the patient's symptoms are not controlled by medication. When immunotherapy is contemplated demonstration of sensitivity to a specific allergenic extract is necessary. An orderly approach to the use of diagnostic tests usually begins with direct skin testing. 5,6,11 THIS PRODUCT IS NOT INTENDED FOR TREATMENT OF PATIENTS WHO DO NOT MANIFEST IMMEDIATE HYPERSENSITIVITY REACTIONS TO THE ALLERGENIC EXTRACT FOLLOWING SKIN TESTING. There are no absolute contraindications; however, extreme caution is necessary when using diagnostic ski

Descriptif du produit:

Individual treatment sets as prescribed by the physician. The allergenic extract contains a variable number of individual doses depending on the patient's sensitivity and maximum tolerated maintenance treatment dose.

Statut de autorisation:

Biologic Licensing Application

Résumé des caractéristiques du produit

                                TREATMENT SET TS349930 - TREATMENT SET TS349930 INJECTION, SOLUTION
TREATMENT SET TS349931 - TREATMENT SET TS349931 INJECTION, SOLUTION
TREATMENT SET TS349945 - TREATMENT SET TS349945 INJECTION, SOLUTION
TREATMENT SET TS350093 - TREATMENT SET TS350093 INJECTION, SOLUTION
TREATMENT SET TS350094 - TREATMENT SET TS350094 INJECTION, SOLUTION
TREATMENT SET TS350242 - TREATMENT SET TS350242 INJECTION, SOLUTION
TREATMENT SET TS350256 - TREATMENT SET TS350256 INJECTION, SOLUTION
TREATMENT SET TS350257 - TREATMENT SET TS350257 INJECTION, SOLUTION
ANTIGEN LABORATORIES, INC.
----------
ALLERGENIC EXTRACTS
INDIVIDUAL TREATMENT VIAL
WARNINGS
INDIVIDUAL ALLERGENIC EXTRACT TREATMENT VIAL IS INTENDED FOR USE BY
PHYSICIANS WHO ARE
EXPERIENCED IN THE ADMINISTRATION OF ALLERGENIC EXTRACTS FOR
IMMUNOTHERAPY AND THE
EMERGENCY CARE OF ANAPHYLAXIS, OR FOR USE UNDER THE GUIDANCE OF AN
ALLERGY SPECIALIST.
INDIVIDUAL ALLERGENIC EXTRACT TREATMENT VIALS ARE NOT DIRECTLY
INTERCHANGEABLE WITH OTHER
ALLERGENIC EXTRACTS. THE INITIAL DOSE MUST BE BASED ON SKIN TESTING AS
DESCRIBED IN THE
DOSAGE AND ADMINISTRATION SECTION OF THIS INSERT. PATIENTS BEING
SWITCHED FROM OTHER TYPES
OF EXTRACT TO INDIVIDUAL TREATMENT VIALS SHOULD BE STARTED AS THOUGH
THEY WERE COMING UNDER
TREATMENT FOR THE FIRST TIME. PATIENTS SHOULD BE INSTRUCTED TO
RECOGNIZE ADVERSE REACTION
SYMPTOMS AND CAUTIONED TO CONTACT THE PHYSICIAN'S OFFICE IF REACTION
SYMPTOMS OCCUR. AS
WITH ALL ALLERGENIC EXTRACTS, SEVERE SYSTEMIC REACTIONS MAY OCCUR. IN
CERTAIN INDIVIDUALS,
THESE REACTIONS MAY BE LIFE-THREATENING. PATIENT SHOULD BE OBSERVED
FOR AT LEAST 20 MINUTES
FOLLOWING TREATMENT AND EMERGENCY MEASURES AS WELL AS PERSONNEL
TRAINED IN THEIR USE
SHOULD BE IMMEDIATELY AVAILABLE IN THE EVENT OF A LIFE-THREATENING
REACTION.
THIS PRODUCT SHOULD NOT BE INJECTED INTRAVENOUSLY. DEEP SUBCUTANEOUS
ROUTES HAVE PROVEN
TO BE SAFE. SEE THE WARNINGS, PRECAUTIONS, ADVERSE REACTIONS AND
OVERDOSAGE SECTIONS
BELOW.
DESCRIPTION
Allergenic extract in this vial is referred to as an individual
treatment vial
                                
                                Lire le document complet